Over the continuum of prostate cancer treatment, particularly with the use of ADT, a profound degenerative impact is seen on body composition (reduced lean mass, increased fat mass and total body mass) and systemic inflammation (increased interleukin (IL)-6, IL-8, C-reactive protein (CRP), and tumour necrosis factor-α (TNF-α)) [23,24]. This evidence concerns the gene IL6 and prostate carcinoma.